Please Wait.....
Report
Global Cancer Immunotherapy Market - Industry Trends and Forecast to 2031
Market Report I 2023-12-01 I 596 Pages I Data Bridge Market Research
The global cancer immunotherapy market is expected to reach USD 231,338.41 million by 2031 from USD 83,575.21 million in 2023, growing at a CAGR of 14.5% during the forecast period of 2024 to 2031.
Market Segmentation
Global Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Cancer Immunotherapy Market Dynamics
Driver
- Rising prevalence of cancer incidences
Restraint
- Increasing occurrence of immune-related adverse events
Opportunity
- Growing trend towards combination therapies
Market Players
Some of the major market players operating in the global cancer immunotherapy market are:
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Janssen Pharmaceutical
- AstraZeneca
- Gilead Sciences, Inc.
- Eli Lilly and Company
- Amgen Inc.
- Novartis AG
- GSK
- Pfizer Inc.
- Incyte
TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE GLOBAL CANCER IMMUNOTHERAPY MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 86
1.6 MARKETS COVERED 86
2 MARKET SEGMENTATION 90
2.1 MARKETS COVERED 90
2.2 GEOGRAPHICAL SCOPE 91
2.3 YEARS CONSIDERED FOR THE STUDY 92
2.4 DBMR TRIPOD DATA VALIDATION MODEL 93
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
2.6 MULTIVARIATE MODELLING 97
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 97
2.8 MARKET END USER COVERAGE GRID 98
2.9 DBMR MARKET POSITION GRID 99
2.10 VENDOR SHARE ANALYSIS 100
2.11 SECONDARY SOURCES 101
2.12 ASSUMPTIONS 101
3 EXECUTIVE SUMMARY 102
4 PREMIUM INSIGHTS 104
4.1 PESTAL ANALYSIS 107
4.2 PORTERS 5 FORCES 108
5 GLOBAL CANCER IMMUNOTHERAPY MARKET: REGULATIONS 109
6 MARKET OVERVIEW 117
6.1 DRIVERS 119
6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 119
6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 119
6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 120
6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 120
6.2 RESTRAINTS 121
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 121
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 121
6.3 OPPORTUNITIES 122
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 122
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 122
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 123
6.4 CHALLENGES 124
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 124
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 124
7 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE 125
7.1 OVERVIEW 126
7.2 CHECKPOINT INHIBITORS 129
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 130
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 130
7.3 MONOCLONAL ANTIBODIES 131
7.3.1 NAKED MONOCLONAL ANTIBODIES 132
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 132
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 132
7.4 VACCINES 133
7.4.1 PROPHYLACTIC VACCINES 134
7.4.2 THERAPEUTIC VACCINES 134
7.5 CELL THERAPIES 134
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 135
7.5.2 T CELL THERAPY 135
7.6 IMMUNOMODULATORS 135
7.6.1 INTERFERONS 136
7.6.2 INTERLEUKINS 136
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 136
7.7 ONCOLYTIC VIRUS 137
8 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER 138
8.1 OVERVIEW 139
8.2 HOSPITALS 142
8.3 ONCOLOGY CLINICS 143
8.4 HOMECARE 143
8.5 OTHERS 144
9 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 145
9.1 OVERVIEW 146
9.2 DIRECT TENDERS 149
9.3 RETAIL SALES 150
9.4 PHARMACIES 150
9.4.1 HOSPITAL 151
9.4.2 RETAIL 151
9.4.3 ONLINE 151
10 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY FORM 152
10.1 OVERVIEW 153
10.2 INTRAVENOUS (IV) 156
10.3 INTRAMUSCULAR 157
10.4 ORAL 157
11 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 158
11.1 OVERVIEW 159
11.2 LUNG CANCER 162
11.2.1 CHECKPOINT INHIBITORS 163
11.2.2 MONOCLONAL ANTIBODIES 163
11.2.3 CELL THERAPIES 163
11.2.4 IMMUNOMODULATORS 163
11.3 BREAST CANCER 164
11.3.1 CHECKPOINT INHIBITORS 164
11.3.2 MONOCLONAL ANTIBODIES 164
11.3.3 CELL THERAPIES 165
11.3.4 IMMUNOMODULATORS 165
11.4 MELANOMA 165
11.4.1 CHECKPOINT INHIBITORS 166
11.4.2 MONOCLONAL ANTIBODIES 166
11.4.3 CELL THERAPIES 166
11.4.4 IMMUNOMODULATORS 166
11.4.5 ONCOLYTIC VIRUS 166
11.5 MULTIPLE MYELOMA 167
11.5.1 CHECKPOINT INHIBITORS 167
11.5.2 MONOCLONAL ANTIBODIES 167
11.5.3 CELL THERAPIES 167
11.5.4 IMMUNOMODULATORS 168
11.6 PROSTATE CANCER 168
11.6.1 CHECKPOINT INHIBITORS 168
11.6.2 MONOCLONAL ANTIBODIES 169
11.6.3 CELL THERAPIES 169
11.6.4 IMMUNOMODULATORS 169
11.6.5 VACCINES 169
11.7 OVARIAN CANCER 169
11.7.1 CHECKPOINT INHIBITORS 170
11.7.2 MONOCLONAL ANTIBODIES 170
11.7.3 CELL THERAPIES 170
11.7.4 IMMUNOMODULATORS 170
11.8 CERVICAL CANCER 171
11.8.1 CHECKPOINT INHIBITORS 171
11.8.2 MONOCLONAL ANTIBODIES 171
11.8.3 VACCINES 172
11.8.4 CELL THERAPIES 172
11.8.5 IMMUNOMODULATORS 172
11.9 STOMACH CANCER 172
11.9.1 CHECKPOINT INHIBITORS 173
11.9.2 MONOCLONAL ANTIBODIES 173
11.9.3 CELL THERAPIES 173
11.9.4 IMMUNOMODULATORS 173
11.10 COLORECTAL CANCER 173
11.10.1 CHECKPOINT INHIBITORS 174
11.10.2 MONOCLONAL ANTIBODIES 174
11.10.3 CELL THERAPIES 174
11.10.4 IMMUNOMODULATORS 174
11.11 HEAD AND NECK CANCER 175
11.11.1 CHECKPOINT INHIBITORS 175
11.11.2 MONOCLONAL ANTIBODIES 175
11.11.3 CELL THERAPIES 175
11.11.4 IMMUNOMODULATORS 176
11.12 OTHERS 176
11.12.1 CHECKPOINT INHIBITORS 176
11.12.2 MONOCLONAL ANTIBODIES 176
11.12.3 VACCINES 177
11.12.4 CELL THERAPIES 177
11.12.5 IMMUNOMODULATORS 177
12 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION 178
12.1 OVERVIEW 179
12.2 NORTH AMERICA 182
12.2.1 U.S. 190
12.2.2 CANADA 198
12.2.3 MEXICO 206
12.3 EUROPE 214
12.3.1 GERMANY 222
12.3.2 FRANCE 230
12.3.3 ITALY 238
12.3.4 SPAIN 246
12.3.5 U.K. 254
12.3.6 SWITZERLAND 262
12.3.7 NETHERLANDS 270
12.3.8 RUSSIA 278
12.3.9 TURKEY 286
12.3.10 POLAND 294
12.3.11 HUNGARY 302
12.3.12 LITHUANIA 310
12.3.13 AUSTRIA 318
12.3.14 IRELAND 326
12.3.15 NORWAY 334
12.3.16 REST OF EUROPE 342
12.4 ASIA-PACIFIC 343
12.4.1 CHINA 352
12.4.2 JAPAN 360
12.4.3 INDIA 368
12.4.4 SOUTH KOREA 376
12.4.5 AUSTRALIA 384
12.4.6 SINGAPORE 393
12.4.7 THAILAND 402
12.4.8 INDONESIA 410
12.4.9 PHILIPPINES 419
12.4.10 MALAYSIA 428
12.4.11 VIETNAM 436
12.4.12 REST OF ASIA-PACIFIC 444
12.5 SOUTH AMERICA 445
12.5.1 BRAZIL 453
12.5.2 ARGENTINA 461
12.5.3 PERU 469
12.5.4 REST OF SOUTH AMERICA 477
12.6 MIDDLE EAST AND AFRICA 478
12.6.1 SOUTH AFRICA 486
12.6.2 SAUDI ARABIA 494
12.6.3 U.A.E. 502
12.6.4 EGYPT 510
12.6.5 ISRAEL 518
12.6.6 OMAN 526
12.6.7 QATAR 534
12.6.8 BAHRAIN 542
12.6.9 REST OF MIDDLE EAST AND AFRICA 550
13 GLOBAL CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 551
13.1 COMPANY SHARE ANALYSIS: GLOBAL 551
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 552
13.3 COMPANY SHARE ANALYSIS: EUROPE 553
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 554
14 SWOT ANALYSIS 555
15 COMPANY PROFILES 556
15.1 MERCK & CO., INC. 556
15.1.1 COMPANY SNAPSHOT 556
15.1.2 REVENUE ANALYSIS 556
15.1.3 COMPANY SHARE ANALYSIS 557
15.1.4 PRODUCT PORTFOLIO 557
15.1.5 RECENT DEVELOPMENTS 557
15.2 F. HOFFMANN-LA ROCHE LTD 558
15.2.1 COMPANY SNAPSHOT 558
15.2.2 REVENUE ANALYSIS 558
15.2.3 COMPANY SHARE ANALYSIS 559
15.2.4 PRODUCT PORTFOLIO 559
15.2.5 RECENT DEVELOPMENTS 559
15.3 BRISTOL-MYERS SQUIBB COMPANY 561
15.3.1 COMPANY SNAPSHOT 561
15.3.2 REVENUE ANALYSIS 561
15.3.3 COMPANY SHARE ANALYSIS 562
15.3.4 PRODUCT PORTFOLIO 562
15.3.5 RECENT DEVELOPMENTS 563
15.4 JANSSEN GLOBAL SERVICES, LLC 564
15.4.1 COMPANY SNAPSHOT 564
15.4.2 REVENUE ANALYSIS 564
15.4.3 COMPANY SHARE ANALYSIS 565
15.4.4 PRODUCT PORTFOLIO 565
15.4.5 RECENT DEVELOPMENTS 566
15.5 ASTRAZENECA 567
15.5.1 COMPANY SNAPSHOT 567
15.5.2 REVENUE ANALYSIS 567
15.5.3 COMPANY SHARE ANALYSIS 568
15.5.4 PRODUCT PORTFOLIO 568
15.5.5 RECENT DEVELOPMENTS 569
15.6 ABBVIE INC. 570
15.6.1 COMPANY SNAPSHOT 570
15.6.2 PIPELINE PORTFOLIO 570
15.6.3 RECENT DEVELOPMENTS 570
15.7 AMGEN INC. 571
15.7.1 COMPANY SNAPSHOT 571
15.7.2 REVENUE ANALYSIS 572
15.7.3 PIPELINE PORTFOLIO 572
15.7.4 PRODUCT PORTFOLIO 573
15.7.5 RECENT DEVELOPMENTS 573
15.8 ATARA BIOTHERAPEUTICS, INC. 574
15.8.1 COMPANY SNAPSHOT 574
15.8.2 PIPELINE PORTFOLIO 574
15.8.3 RECENT DEVELOPMENTS 574
15.9 BAYER AG 575
15.9.1 COMPANY SNAPSHOT 575
15.9.2 PIPELINE PORTFOLIO 575
15.9.3 RECENT DEVELOPMENTS 575
15.10 CELLDEX THERAPEUTICS. 577
15.10.1 COMPANY SNAPSHOT 577
15.10.2 PIPELINE PORTFOLIO 577
15.10.3 RECENT DEVELOPMENTS 577
15.11 CELLECTIS 578
15.11.1 COMPANY SNAPSHOT 578
15.11.2 PIPELINE PORTFOLIO 578
15.11.3 RECENT DEVELOPMENTS 578
15.12 GILEAD SCIENCES, INC. 579
15.12.1 COMPANY SNAPSHOT 579
15.12.2 REVENUE ANALYSIS 579
15.12.3 PRODUCT PORTFOLIO 580
15.12.4 RECENT DEVELOPMENTS 580
15.13 GSK PLC. 581
15.13.1 COMPANY SNAPSHOT 581
15.13.2 REVENUE ANALYSIS 581
15.13.3 PRODUCT PORTFOLIO 582
15.13.4 RECENT DEVELOPMENTS 582
15.14 INCYTE. 583
15.14.1 COMPANY SNAPSHOT 583
15.14.2 REVENUE ANALYSIS 583
15.14.3 PRODUCT PORTFOLIO 584
15.14.4 RECENT DEVELOPMENTS 584
15.15 LILLY. 585
15.15.1 COMPANY SNAPSHOT 585
15.15.2 REVENUE ANALYSIS 586
15.15.3 PRODUCT PORTFOLIO 586
15.15.4 RECENT DEVELOPMENTS 587
15.16 NOVARTIS AG 588
15.16.1 COMPANY SNAPSHOT 588
15.16.2 REVENUE ANALYSIS 588
15.16.3 PIPELINE PORTFOLIO 589
15.16.4 PRODUCT PORTFOLIO 589
15.16.5 RECENT DEVELOPMENTS 589
15.17 PFIZER INC. 590
15.17.1 COMPANY SNAPSHOT 590
15.17.2 REVENUE ANALYSIS 590
15.17.3 PRODUCT PORTFOLIO 591
15.17.4 RECENT DEVELOPMENTS 591
16 QUESTIONNAIRE 592
17 RELATED REPORTS 596
15.12 GILEAD SCIENCES, INC. 579
15.12.1 COMPANY SNAPSHOT 579
15.12.2 REVENUE ANALYSIS 579
15.12.3 PRODUCT PORTFOLIO 580
15.12.4 RECENT DEVELOPMENTS 580
15.13 GSK PLC. 581
15.13.1 COMPANY SNAPSHOT 581
15.13.2 REVENUE ANALYSIS 581
15.13.3 PRODUCT PORTFOLIO 582
15.13.4 RECENT DEVELOPMENTS 582
15.14 INCYTE. 583
15.14.1 COMPANY SNAPSHOT 583
15.14.2 REVENUE ANALYSIS 583
15.14.3 PRODUCT PORTFOLIO 584
15.14.4 RECENT DEVELOPMENTS 584
15.15 LILLY. 585
15.15.1 COMPANY SNAPSHOT 585
15.15.2 REVENUE ANALYSIS 586
15.15.3 PRODUCT PORTFOLIO 586
15.15.4 RECENT DEVELOPMENTS 587
15.16 NOVARTIS AG 588
15.16.1 COMPANY SNAPSHOT 588
15.16.2 REVENUE ANALYSIS 588
15.16.3 PIPELINE PORTFOLIO 589
15.16.4 PRODUCT PORTFOLIO 589
15.16.5 RECENT DEVELOPMENTS 589
15.17 PFIZER INC. 590
15.17.1 COMPANY SNAPSHOT 590
15.17.2 REVENUE ANALYSIS 590
15.17.3 PRODUCT PORTFOLIO 591
15.17.4 RECENT DEVELOPMENTS 591
16 QUESTIONNAIRE 592
17 RELATED REPORTS 596
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security